What is Pfizer's noncontrolling interests in subsidiaries?

Pfizer (PFE) reported noncontrolling interests in subsidiaries of $303M in Q1 2026.

How has Pfizer's noncontrolling interests in subsidiaries changed year-over-year?

Pfizer's noncontrolling interests in subsidiaries increased by 1.3% year-over-year, from $299M to $303M.

What is the long-term trend for Pfizer's noncontrolling interests in subsidiaries?

Over 5 years (2020 to 2025), Pfizer's noncontrolling interests in subsidiaries has grown at a 4.9% compound annual growth rate (CAGR), from $235M to $299M.

Pfizer PFE Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Bristol-Myers SquibbBMY

$34M-42.4%

Merck & Co.MRK

——

Roivant SciencesROIV

——

Royalty PharmaRPRX

——

AbbottABT

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$147.73B+11.1%

Enterprise value$210.4B+9.2%

P/E12.2×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's noncontrolling interests in subsidiaries?: Pfizer (PFE) reported noncontrolling interests in subsidiaries of $303M in Q1 2026.
How has Pfizer's noncontrolling interests in subsidiaries changed year-over-year?: Pfizer's noncontrolling interests in subsidiaries increased by 1.3% year-over-year, from $299M to $303M.
What is the long-term trend for Pfizer's noncontrolling interests in subsidiaries?: Over 5 years (2020 to 2025), Pfizer's noncontrolling interests in subsidiaries has grown at a 4.9% compound annual growth rate (CAGR), from $235M to $299M.